Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
$0.16
-3.4%
$0.19
$0.16
$1.09
$4.79M0.191.87 million shs117,156 shs
Assure Holdings Corp. stock logo
IONM
Assure
$0.86
+17.8%
$0.49
$0.20
$4.17
$5.78M1.941.19 million shs512,058 shs
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
$0.06
-12.8%
$0.08
$0.05
$1.25
$2.29M-0.0681,518 shs82,647 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$18.72
+1.2%
$17.65
$14.51
$22.99
$65.71M0.67,910 shs5,414 shs
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$2.81
+1.8%
$3.93
$2.60
$70.00
$15.48M0.11273,109 shs406,237 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
-0.89%+2.27%-14.55%-46.19%-80.31%
Assure Holdings Corp. stock logo
IONM
Assure
+6.29%+15.63%+55.65%+239.22%-74.39%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
-9.72%-14.47%-26.09%-27.78%-91.85%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
-1.33%+1.31%+7.37%-14.15%+15.99%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
+1.47%-6.12%-7.38%-32.85%-92.03%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Assure Holdings Corp. stock logo
IONM
Assure
1.0975 of 5 stars
2.05.00.00.02.90.00.6
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
1.8158 of 5 stars
3.50.00.04.50.61.70.0
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
N/AN/AN/AN/A
Assure Holdings Corp. stock logo
IONM
Assure
N/AN/A$4.00354.60% Upside
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
3.00
Buy$2.504,309.17% Upside
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
$7.16M0.69N/AN/A($0.03) per share-5.54
Assure Holdings Corp. stock logo
IONM
Assure
$10.98M0.54N/AN/A$5.20 per share0.17
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
$80K28.60N/AN/A($0.41) per share-0.14
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$46.09M1.43$2.24 per share8.37$8.91 per share2.10
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$7.19M2.10N/AN/A($6.91) per share-0.40

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
-$81.66M-$1.24N/AN/A-166.79%-35.31%-13.43%5/9/2024 (Estimated)
Assure Holdings Corp. stock logo
IONM
Assure
-$30.11MN/A0.00N/A-400.68%-6,320.92%-169.03%5/8/2024 (Estimated)
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
-$14.14M-$0.39N/AN/AN/AN/A-142.69%N/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$7.07M$0.7524.96N/A5.59%8.97%5.40%5/2/2024 (Estimated)
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-$50.08MN/A0.00N/A-696.19%N/A-129.79%5/6/2024 (Confirmed)

Latest AFIB, TTOO, PDEX, IONM, and NMRD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024N/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/AN/A
2/12/2024Q3 2024
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/A-$0.12-$0.12-$0.17N/AN/A
2/8/2024Q2 2024
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/A$0.14+$0.14$0.14N/A$12.59 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
N/AN/AN/AN/AN/A
Assure Holdings Corp. stock logo
IONM
Assure
N/AN/AN/AN/AN/A
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
1.10
2.44
2.22
Assure Holdings Corp. stock logo
IONM
Assure
N/A
1.50
1.50
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/A
0.19
0.03
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.26
3.66
2.16
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/A
0.45
0.36

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
56.91%
Assure Holdings Corp. stock logo
IONM
Assure
3.33%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
4.41%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
15.28%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
23.18%

Insider Ownership

CompanyInsider Ownership
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
3.50%
Assure Holdings Corp. stock logo
IONM
Assure
3.80%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
41.60%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
42.60%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acutus Medical, Inc. stock logo
AFIB
Acutus Medical
23029.72 million28.68 millionOptionable
Assure Holdings Corp. stock logo
IONM
Assure
1276.72 million6.47 millionNot Optionable
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
3640.35 million23.57 millionOptionable
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
1453.51 million2.02 millionNot Optionable
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
1135.51 million5.51 millionOptionable

AFIB, TTOO, PDEX, IONM, and NMRD Headlines

SourceHeadline
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
globenewswire.com - April 24 at 9:00 AM
T2 Biosystems (NASDAQ:TTOO) versus Anika Therapeutics (NASDAQ:ANIK) Head to Head ContrastT2 Biosystems (NASDAQ:TTOO) versus Anika Therapeutics (NASDAQ:ANIK) Head to Head Contrast
americanbankingnews.com - April 22 at 1:26 AM
T2 Biosystems, Inc. (NASDAQ:TTOO) Short Interest UpdateT2 Biosystems, Inc. (NASDAQ:TTOO) Short Interest Update
americanbankingnews.com - April 15 at 3:22 AM
T2 Biosystems converts $15M loan to equity, aims for Nasdaq complianceT2 Biosystems converts $15M loan to equity, aims for Nasdaq compliance
investing.com - April 13 at 6:55 PM
T2 Biosystems, Inc.: T2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityT2 Biosystems, Inc.: T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
finanznachrichten.de - April 12 at 9:52 AM
T2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityT2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
globenewswire.com - April 11 at 4:05 PM
T2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.T2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
finanznachrichten.de - March 28 at 11:09 AM
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
globenewswire.com - March 28 at 9:00 AM
T2 Biosystems, Inc.: T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesT2 Biosystems, Inc.: T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
finanznachrichten.de - March 20 at 4:39 PM
T2 Biosystems Targets Commercial Launch Of T2Lyme Panel In Q3 - Quick FactsT2 Biosystems Targets Commercial Launch Of T2Lyme Panel In Q3 - Quick Facts
markets.businessinsider.com - March 20 at 4:39 PM
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesT2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
globenewswire.com - March 20 at 7:30 AM
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business UpdatesT2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
globenewswire.com - March 19 at 9:00 AM
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance PanelT2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
globenewswire.com - March 18 at 9:00 AM
TTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq ComplianceTTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq Compliance
investorplace.com - March 12 at 3:16 PM
T2 Biosystems Receives Extension From Nasdaq to Comply With Listing RequirementT2 Biosystems Receives Extension From Nasdaq to Comply With Listing Requirement
360dx.com - March 12 at 10:40 AM
T2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementT2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
finanznachrichten.de - March 12 at 10:40 AM
T2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementT2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
globenewswire.com - March 12 at 9:00 AM
T2 Biosystems IncT2 Biosystems Inc
money.usnews.com - February 16 at 10:34 PM
T2 Biosystems (TTOO) share price stays stable post Q4 earningsT2 Biosystems (TTOO) share price stays stable post Q4 earnings
invezz.com - February 16 at 12:34 PM
T2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call TranscriptT2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 16 at 12:34 PM
T2 Biosystems (TTOO) share price stays stable post Q4 earningsT2 Biosystems (TTOO) share price stays stable post Q4 earnings
invezz.com - February 16 at 11:09 AM
T2 Biosystems, Inc.: T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaT2 Biosystems, Inc.: T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
finanznachrichten.de - February 16 at 7:34 AM
Q4 2023 T2 Biosystems Inc Earnings CallQ4 2023 T2 Biosystems Inc Earnings Call
finance.yahoo.com - February 16 at 7:34 AM
T2 Biosystems Preliminary Q4 Revenues Down 69 PercentT2 Biosystems Preliminary Q4 Revenues Down 69 Percent
360dx.com - February 15 at 9:30 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acutus Medical logo

Acutus Medical

NASDAQ:AFIB
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. The company was incorporated in 2011 and is headquartered in Carlsbad, California.
Assure logo

Assure

NASDAQ:IONM
Assure Holdings Corp., through its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services in the United States. It offers services in the areas of neurosurgery, spine, cardiovascular, orthopedic, ear, nose, throat, and other surgical procedures. The company delivers various clinical and operational services, including scheduling of the interoperative neurophysiologist and supervising practitioner, real time monitoring, patient advocacy, and billing services to support surgeons and medical facilities during invasive procedures. Assure Holdings Corp. is based in Englewood, Colorado.
Nemaura Medical logo

Nemaura Medical

NASDAQ:NMRD
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Pro-Dex logo

Pro-Dex

NASDAQ:PDEX
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
T2 Biosystems logo

T2 Biosystems

NASDAQ:TTOO
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.